Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01452815 · ClinicalTrials.gov registry record · Phase 2
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
A Phase 2 study, sponsored by Tranzyme.
- Completed
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT01452815: Completed Phase 2 study, sponsored by Tranzyme.
NCT01452815 is a Phase 2 study that has completed, run by Tranzyme. The registered enrollment target is 201 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01452815, a Phase 2 study, has completed, sponsored by Tranzyme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.
Interventions
- DRUG Placebo
- DRUG 10mg TZP-102
- DRUG 20mg TZP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT01452815 record still lists
NCT01452815 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01452815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01452815 about?
NCT01452815 is a clinical study titled "Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis". The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily for 12 weeks, in diabetic subjects with symptoms associated with gastrop...
What is the current status of trial NCT01452815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2011-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01452815?
The interventions under investigation include: Placebo (DRUG), 10mg TZP-102 (DRUG), 20mg TZP-102 (DRUG).
Who is sponsoring clinical trial NCT01452815?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01452815's enrollment target sits among peer trials
201 302nd of 2000 higher than 1,697 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia